Bullseye Asset Management LLC Has $1.66 Million Stake in NeoGenomics, Inc. $NEO

Bullseye Asset Management LLC grew its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 4.6% during the second quarter, HoldingsChannel.com reports. The firm owned 226,860 shares of the medical research company’s stock after acquiring an additional 10,000 shares during the quarter. Bullseye Asset Management LLC’s holdings in NeoGenomics were worth $1,659,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Brooklyn Investment Group bought a new stake in shares of NeoGenomics in the first quarter valued at approximately $35,000. CWM LLC increased its stake in NeoGenomics by 42.6% during the 1st quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock worth $60,000 after acquiring an additional 1,883 shares during the period. AlphaQuest LLC acquired a new position in NeoGenomics in the 1st quarter valued at $60,000. Capstone Financial Advisors Inc. bought a new stake in shares of NeoGenomics during the 2nd quarter valued at $73,000. Finally, Moors & Cabot Inc. grew its holdings in shares of NeoGenomics by 20.0% during the 2nd quarter. Moors & Cabot Inc. now owns 12,000 shares of the medical research company’s stock worth $88,000 after purchasing an additional 2,000 shares in the last quarter. 98.50% of the stock is owned by institutional investors.

NeoGenomics Price Performance

NEO stock opened at $11.61 on Tuesday. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -13.19 and a beta of 1.67. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.91 and a quick ratio of 3.58. The company has a 50 day simple moving average of $9.58 and a 200 day simple moving average of $7.97. NeoGenomics, Inc. has a 1 year low of $4.72 and a 1 year high of $19.11.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, October 28th. The medical research company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.01. The firm had revenue of $187.80 million for the quarter, compared to analysts’ expectations of $183.85 million. NeoGenomics had a negative net margin of 16.00% and a negative return on equity of 3.36%. The company’s revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.05 earnings per share. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Research analysts anticipate that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Needham & Company LLC boosted their price target on NeoGenomics from $8.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, August 29th. TD Cowen raised their target price on shares of NeoGenomics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, September 12th. Morgan Stanley set a $8.00 target price on shares of NeoGenomics and gave the company an “equal weight” rating in a research report on Wednesday, July 30th. BTIG Research reiterated a “neutral” rating on shares of NeoGenomics in a research report on Wednesday, July 30th. Finally, Piper Sandler set a $11.00 price objective on shares of NeoGenomics and gave the company an “overweight” rating in a research report on Monday, August 4th. Seven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $13.11.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.